comparemela.com

Latest Breaking News On - Nonmetastatic castration resistant prostate cancer - Page 1 : comparemela.com

Importance of Quality of Life When Choosing Therapy for nmCRPC

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

Key updatesMetastatic prostate cancer treatmentLife when choosing therapyProstate cancerNonmetastatic castration resistant prostate cancerAr inhibitorsAndrogen receptor inhibitorsQuality of lifeQol dataSpartan trialSpartan studyProsper trialProsper studyAramis trialAramis study

AR Inhibitors in nmCRPC: Real-World Data

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

Key updatesMetastatic prostate cancer treatmentReal world dataProstate cancerNonmetastatic castration resistant prostate cancerAr inhibitorsAndrogen receptor inhibitorsDear studyDear trialSpartan trialSpartan studyProsper trialProsper studyAramis trialAramis study

nmCRPC: Clinical Trial Data on AR Inhibitors

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Key updatesMetastatic prostate cancer treatmentClinical trial dataProstate cancerNonmetastatic castration resistant prostate cancerSpartan trialSpartan studyProsper trialProsper studyAramis trialAramis studyMetastasis free survivalMfs survivalOverall survivalSurvival dataAr inhibitors

Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Key updatesMetastatic prostate cancer treatmentNon metastatic castration resistant prostateProstate cancerNonmetastatic castration resistant prostate cancerMetastasis free survivalMfs survivalPsa doublingPsa doubling timeProstate cancer imagingPsma petPsma pet scan

vimarsana © 2020. All Rights Reserved.